With only a few weeks left in the year, concern was rising over why MAPS PBC hadn’t yet submitted its NDA. All that, however, was put...
–Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) announced positive topline results from its Phase 2b clinical trial of MM-120 (lysergide d-tartrate)...
The personal yet global struggle with mental health may be more visible now than ever before. Yet many people still find it difficult to access the...
A researcher with the University of Tennessee Institute of Agriculture has been appointed to a regional evaluation and training center addressing diseases...
A new study carried out by researchers at Concordia’s School of Health provides a new way of looking at the spine. The research reveals the way one...
In a joint effort spanning the Department of Defense and the Department of Health and Human Services, the Defense Advanced Research Projects Agency (DARPA)...
Patients with lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), often undergo progressive kidney damage, with approximately...
DETROIT (December 13, 2023) – Published results of a large, national heart attack study show that patients with a life-threatening complication known...
MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced...